Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

What goes up must come down: biomarkers and novel biologicals in severe asthma.

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology - 1 Jul 2015

Hilvering B, Pavord I D

Abstract excerpt

Asthma is a heterogeneous airway disease characterized by typical symptoms in combination with variable airway obstruction. Most patients with asthma have well controlled symptoms and a low risk of asthma attacks with inhaled corticosteroid (ICS) treatment. However, a clinically important subgroup (~ 10%) remains symptomatic and/or at risk of asthma attacks despite maximum inhaled therapy. Patients with severe...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-Asthmatic Agents
Share to Antibodies, Monoclonal

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Asthma

Share to Biological Factors

Share to Biomarkers

Share to Cytokines

Share to Molecular Targeted Therapy

Share to Th2 Cells

Source

Identifiers

PMID: 25640208
DOI: 10.1111/cea.12500

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

What goes up must come down: biomarkers and novel biologicals in severe asthma.PMID 25640208Read ↗

Controversies and opportunities in severe asthma.Semantic proximity Read ↗

Inflammation in Asthma: Mechanistic Insights and the Role of Biologics in Therapeutic FrontiersSemantic proximity Read ↗

Pharmacological Therapy of Bronchial Asthma: The Role of Biologicals.Semantic proximity Read ↗

Asthma phenotyping: a necessity for improved therapeutic precision and new targeted therapies.Semantic proximity Read ↗

Inflammatory biomarkers in severe asthma.Semantic proximity Read ↗

Biologic Therapy in Severe Asthma: A Phenotype-Driven and Targeted ApproachSemantic proximity Read ↗

Biologics in severe asthma: the overlap endotype - opportunities and challenges.Semantic proximity Read ↗

Characteristics, phenotypes, mechanisms and management of severe asthma.Semantic proximity Read ↗

Molecular phenotyping and biomarker development: are we on our way towards targeted therapy for severe asthma?Semantic proximity Read ↗

Biomarkers in asthma, potential for therapeutic intervention.Semantic proximity Read ↗

Biologic Therapy and Novel Molecular Targets of Severe Asthma.Semantic proximity Read ↗

Asthma phenotypes and the use of biologic medications in asthma and allergic disease: the next steps toward personalized care.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.